Table 4.
Difference in means and 95% confidence intervals for extended nitric oxide measurements
| Mean difference | 95% CI | Significance | ||
|---|---|---|---|---|
| FENO (ppb) | ||||
| FPSM | vs. FPSM/FP | 7.85 | (–1.10, 16.80) | 0.094 |
| vs. FPSM/BDP | 10.41 | (1.46, 19.36) | 0.048 | |
| vs. FPSM/PRED | 11.18 | (2.23, 20.13) | 0.041 | |
| FPSM/FP | vs. FPSM/BDP | 2.57 | (–6.38, 11.52) | 0.485 |
| vs. FPSM/PRED | 3.33 | (–5.62, 12.28) | 0.379 | |
| FPSM/BDP | vs. FPSM/PRED | 0.76 | (–8.19, 9.71) | 0.829 |
| JawNO (nl s−1) | ||||
| FPSM | vs. FPSM/FP | 765.1 | (–103.5, 1634) | 0.093 |
| vs. FPSM/BDP | 932.6 | (63.96, 1801) | 0.049 | |
| vs. FPSM/PRED | 1027 | (158.6, 1896) | 0.047 | |
| FPSM/FP | vs. FPSM/BDP | 167.5 | (–701.1, 1036) | 0.630 |
| vs. FPSM/PRED | 262.1 | (–606.5, 1131) | 0.465 | |
| FPSM/BDP | vs. FPSM/PRED | 94.63 | (–774.0, 963.3) | 0.783 |
| CANO (ppb) | ||||
| FPSM | vs. FPSM/FP | –0.56 | (–2.35, 1.24) | 0.459 |
| vs. FPSM/BDP | –0.32 | (–2.12, 1.47) | 0.651 | |
| vs. FPSM/PRED | –0.15 | (–1.94, 1.64) | 0.832 | |
| FPSM/FP | vs. FPSM/BDP | 0.23 | (–1.56, 2.03) | 0.741 |
| vs. FPSM/PRED | 0.41 | (–1.39, 2.20) | 0.631 | |
| FPSM/BDP | vs. FPSM/PRED | 0.17 | (–1.62, 1.97) | 0.806 |
| Uncorrected CANO (ppb) | ||||
| FPSM | vs. FPSM/FP | 0.20 | (–1.33, 1.73) | 0.740 |
| vs. FPSM/BDP | 0.60 | (–0.92, 2.13) | 0.355 | |
| vs. FPSM/PRED | 0.87 | (–0.66, 2.40) | 0.213 | |
| FPSM/FP | vs. FPSM/BDP | 0.40 | (–1.13, 1.93) | 0.520 |
| vs. FPSM/PRED | 0.67 | (–0.86, 2.19) | 0.312 | |
| FPSM/BDP | vs. FPSM/PRED | 0.27 | (–1.26, 1.79) | 0.660 |
FP, fluticasone; FPSM, fluticasone/salmeterol; BDP, beclomethasone diproprionate; PRED, prednisolone.